Pinsent Masons advises DCC Healthcare on acquisition of pharma business

27 Dec 2012 | 01:14 pm | 1 min. read

International law firm Pinsent Masons has advised DCC Healthcare on the conditional agreement to acquire Kent Pharmaceutical (Holdings) Limited, a leading British generic pharmaceuticals company, for €71.2 million (Stg£58.0 million). Completion of the acquisition is conditional on approval from the Irish Competition Authority and it is anticipated that the transaction will complete in early 2013.

Kent Pharma is involved in the development, manufacture, sales, marketing and distribution of generic pharmaceuticals for the British, Irish and international markets. It principally sells into the retail pharmacy channel as well as into to hospitals, other generic pharma companies and international distributors.  The business is headquartered in Ashford, Kent and has an Irish manufacturing site in Ireland.

DCC Healthcare, which has been active in the pharmaceutical market since 2002, is part of Dublin-based support services company DCC plc.

Tommy Breen, Chief Executive of DCC plc, said: "The acquisition of Kent Pharma is a material step forward for DCC Healthcare. For some time DCC has believed that there is an opportunity to build a substantial pharma business principally focused on established niche generic products that are a number of years post patent expiry.  Such products are well positioned to benefit from the macro trend for healthcare systems to seek to meet the increasing demands of ageing populations with more cost effective healthcare solutions.  In addition, the pharma market is fragmented offering value enhancing bolt on acquisition opportunities, in particular where a strong platform has been established. 

Kent Pharma is an excellent strategic fit for DCC Healthcare's existing pharma business and their combined strengths will create new growth opportunities for DCC."

The Pinsent Masons team was led by Andrew Kerr, Partner and head of the Leeds' corporate team, assisted by Emma Shield and Lucie Miller (corporate) as well as a cross group team of specialist lawyers.

Latest press releases

Show me all press releases

Pinsent Masons advises Bestinver Infra, FCR on acquisition of remaining shares in Irish toll road concession & operation companies

Pinsent Masons has advised Bestinver Infra, FCR on the acquisition of the remaining shares in N6 (Concession) Holdings Limited and N6 (Operations) Ltd, with Japanese co-investor Daiwa Energy & Infrastructure Co. Ltd.

Pinsent Masons advises Sandoz on acquisition of remaining shares in Rowex Joint Venture

Multinational law firm Pinsent Masons has advised Sandoz on the acquisition of the remaining shares in Rowex Limited, a joint venture in Ireland between Sandoz and Rowa Pharmaceuticals.

Pinsent Masons advises Lloyds Bank on £62 million fund to invest in sustainable business and regional development

Multinational law firm Pinsent Masons has advised Lloyds Bank on the launch of a £62 million investment fund to help small businesses across England and Wales access finance to support local jobs and economic activity.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Bestinver Infra, FCR on acquisition of remaining shares in Irish toll road concession & operation companies

Pinsent Masons has advised Bestinver Infra, FCR on the acquisition of the remaining shares in N6 (Concession) Holdings Limited and N6 (Operations) Ltd, with Japanese co-investor Daiwa Energy & Infrastructure Co. Ltd.

Pinsent Masons advises Sandoz on acquisition of remaining shares in Rowex Joint Venture

Multinational law firm Pinsent Masons has advised Sandoz on the acquisition of the remaining shares in Rowex Limited, a joint venture in Ireland between Sandoz and Rowa Pharmaceuticals.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.